Diametric Capital, LP - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 77 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
Diametric Capital, LP ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q1 2023$76,313
+21.1%
50,875
+90.5%
0.04%
-22.9%
Q1 2021$63,000
+200.0%
26,712
+13.3%
0.05%
+200.0%
Q2 2020$21,00023,5670.02%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q3 2020
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,005,379$28,160,0003.29%
Defender Capital, LLC. 4,416,590$3,657,0002.67%
Prescott General Partners LLC 1,851,851$1,534,0000.13%
Laidlaw Wealth Management LLC 107,379$89,0000.06%
Northeast Financial Consultants Inc 523,756$434,0000.05%
Beirne Wealth Consulting Services, LLC 45,000$37,0000.04%
DAFNA Capital Management LLC 95,000$79,0000.03%
Summit X, LLC 30,700$25,0000.01%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 529,039$438,0000.01%
Keudell/Morrison Wealth Management 10,105$8,0000.01%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders